logo
Plus   Neg
Share
Email

Biogen Q3 Profit Tops Estimates; Revenue Up 5% - Quick Facts

Biogen Inc. (BIIB) said it delivered solid performance in the third quarter driven by continued resilience from its MS core business and growth from SPINRAZA and biosimilars. Non-GAAP earnings per share increased 24 percent from previous year. SPINRAZA revenues grew 17 percent from prior year.

Third quarter non-GAAP earnings per share was $9.17 compared to $7.40, last year. On average, 27 analysts polled by Thomson Reuters expected the company to report profit per share of $8.27, for the quarter. Analysts' estimates typically exclude special items.

Third quarter total revenues were $3.60 billion, a 5 percent increase from the third quarter of 2018. Analysts expected revenue of $3.54 billion, for the quarter.

Shares of Biogen Inc. were up more than 34% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT